This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Sanofi. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: Otmane Boussif: Innovator in Antibody Formulations
Introduction
Otmane Boussif is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibody formulations. With a total of two patents to his name, Boussif is recognized for his innovative approaches to treating various diseases.
Latest Patents
Boussif's latest patents include "Uses of a dual V region antibody-like protein" and "Anti-IL-4/anti-IL-13 bispecific antibody formulations." The first patent focuses on the applications of a dual V region antibody-like protein or its fragments. The second patent provides stable pharmaceutical antibody formulations, including lyophilized formulations, that comprise an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system. This formulation is designed to maintain a pH of about 7 and features a low salt concentration to reduce ionic strength. Additionally, it may include a non-ionic surfactant, sugar, and/or a non-ionic stabilizing agent, making it suitable for the treatment of various diseases.
Career Highlights
Otmane Boussif is currently associated with Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to focus on innovative solutions in the pharmaceutical industry. His expertise in antibody formulations has positioned him as a key player in the development of new therapeutic options.
Collaborations
Boussif has collaborated with notable colleagues, including Sophie Carayon and Florent C Bender. These collaborations have contributed to the advancement of research and development in the field of biotechnology.
Conclusion
Otmane Boussif is a distinguished inventor whose work in antibody formulations has the potential to impact the treatment of various diseases. His innovative patents and collaborations highlight his commitment to advancing biotechnology.